Preclinical studies demonstrated that edaravone (ranging from 1.5 to 15 mg/kg) improves motor function, slows symptom progression, and attenuates motor neuron degeneration in transgenic SOD1 rodent models of ALS (Table 2) [223, 224]. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.